OverviewSuggest Edit

Mallinckrodt is a business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies, as well as nuclear imaging products. It focuses on autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology and pulmonology, immunotherapy and neonatal respiratory critical care therapies, analgesics and hemostasis products; and central nervous system drugs.
TypePublic
Founded1867
HQStaines, GB
Websitemallinckrodt.com
Employee Ratings2.9

Latest Updates

Employees (est.) (Dec 2018)3,700(-5%)
Job Openings101
Revenue (FY, 2018)£90.4 M(-16%)
Share Price (Sept 2020)$1.4 (+8%)
Cybersecurity ratingAMore

Key People/Management at Mallinckrodt Pharmaceuticals

Mark Trudeau

Mark Trudeau

President, Chief Executive Officer & Director
Spiro Gavaris

Spiro Gavaris

President, Specialty Generics
Angus Russell

Angus Russell

Chairman of the Board
Mark Casey

Mark Casey

Executive Vice President and Chief Legal Officer
Michele Robertson

Michele Robertson

Senior Vice President and Chief Compliance Officer
Brandi Robinson

Brandi Robinson

Senior Vice President and Chief Communications Officer
Show more

Mallinckrodt Pharmaceuticals Office Locations

Mallinckrodt Pharmaceuticals has offices in Staines, Bedminster, Hazelwood, Webster Groves and in 1 other location
Staines, GB (HQ)
The Causeway, Staines-upon-Thames
Blanchardstown, IE
Main St
Bedminster, US
1425 US-206
Hazelwood, US
675 James S. McDonnell Blvd
Webster Groves, US
385 Marshall Ave
Show all (5)

Mallinckrodt Pharmaceuticals Financials and Metrics

Mallinckrodt Pharmaceuticals Revenue

Embed Graph
View revenue for all periods
Mallinckrodt Pharmaceuticals's revenue was reported to be £90.37 m in FY, 2018
GBP

Revenue (FY, 2018)

90.4m

Gross profit (FY, 2018)

8.4m

Gross profit margin (FY, 2018), %

9.3%

Net income (FY, 2018)

3.9m

EBITDA (FY, 2018)

3.5m

EBIT (FY, 2018)

3.5m

Market capitalization (18-Sept-2020)

115.9m

Closing stock price (18-Sept-2020)

1.4
Mallinckrodt Pharmaceuticals's current market capitalization is $115.9 m.
GBPFY, 1995FY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

20.8m22.0m25.5m26.3m26.7m23.9m28.4m27.8m30.7m28.9m34.3m38.0m36.6m45.4m71.6m65.9m72.6m79.6m89.7m62.6m64.2m65.0m108.0m90.4m

Revenue growth, %

(30%)3%

Cost of goods sold

16.2m16.1m19.7m21.5m19.7m19.9m23.6m22.0m23.8m22.5m27.7m31.6m31.5m36.3m56.0m56.4m65.0m70.6m79.8m56.3m55.4m56.5m99.4m82.0m

Gross profit

4.6m5.9m5.8m4.8m6.9m4.0m4.7m5.8m6.9m6.4m6.6m6.5m5.1m9.0m15.6m9.5m7.6m9.0m9.9m6.3m8.8m8.5m8.6m8.4m
GBPFY, 1995FY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

938.0k315.0k713.0k591.0k155.0k227.0k187.0k548.0k132.0k2.4m3.0k710.0k1.0k1.0k9.6m1.4m403.0k

Accounts Receivable

3.9m4.2m4.4m3.9m4.3m5.0m4.3m5.3m4.6m5.4m5.8m5.8m7.2m8.3m10.2m11.0m11.4m12.7m11.1m13.4m12.4m12.9m19.5m15.6m

Inventories

3.0m4.2m3.5m3.5m4.0m3.2m3.9m4.4m3.6m2.7m2.0m4.0m4.9m6.4m10.0m11.4m12.3m10.8m6.1m4.9m7.0m7.6m7.1m5.3m

Current Assets

8.9m9.4m12.5m10.0m11.4m10.2m10.7m13.7m17.6m22.0m24.4m26.2m29.3m31.5m51.1m45.2m50.5m42.8m43.0m50.1m53.5m58.3m76.6m29.9m
GBPFY, 1995FY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(20.0k)1.0m648.0k(13.0k)1.5m(484.0k)(2.5m)1.3m4.1m3.7m3.6m2.0m1.2m2.7m5.9m3.9m(7.9m)3.3m3.0m1.9m1.9m1.5m4.6m3.9m

Dividends Paid

40.8m

Income Taxes Paid

(748.0k)(528.0k)(117.0k)
GBPFY, 1995

Financial Leverage

1.5 x
Show all financial metrics

Mallinckrodt Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Mallinckrodt Pharmaceuticals Online and Social Media Presence

Embed Graph

Mallinckrodt Pharmaceuticals News and Updates

Shares of Mallinckrodt Pharmaceuticals up 0.5% after company announces generics business spin-off

Shares of Mallinckrodt PLC were up 0.4% in premarket trade Thursday after the company announced it was planning to spin off its generics business to its shareholders. The spin-off, which is projected to be completed in the second half of 2019, will result in two publicly traded companies, Mallinckr…

Mallinckrodt Pharmaceuticals Blogs

Sarcoidosis Awareness and Education More Important Than Ever During Global Health Crisis

As the impact of the coronavirus continues to unfold, it’s critical that we recognize the increased challenges and uncertainties facing people living with rare diseases like sarcoidosis. Sarcoidosis is a complex, multi-system inflammatory disease, most […] The post Sarcoidosis Awareness and Educatio…

Courage in Action, an Interview with Erica Ruppert, MSN, CNS, ANP-BC

A day before heading to a prominent New York City hospital to volunteer at the epicenter of the United States’ coronavirus outbreak, Mallinckrodt employee, Erica Ruppert, talked to us about why she answered the call […] The post Courage in Action, an Interview with Erica Ruppert, MSN, CNS, ANP-BC ap…

Mallinckrodt Celebrates Diversity & Inclusion During Black History Month

Black History Month is a time to recognize the central role that African Americans play in shaping the history and culture of the United States. To help start conversations throughout the month of February, MNK […] The post Mallinckrodt Celebrates Diversity & Inclusion During Black History Month…

Patient Advocacy in the Rare Disease Community

Worldwide, over 440 million persons are living with rare diseases (1) , including an estimated 30 million Americans (2). On February 29th, the world will raise awareness for this community on Rare Disease Day. Rare Disease Day is […] The post Patient Advocacy in the Rare Disease Community appeared f…

Mallinckrodt Employee Helps Bring the Joy of the Holiday Season to Families in Need

Today’s story is the final entry in the #MNKGivesBack series, highlighting Mallinckrodt’s Global Month of Service, a company-wide initiative encouraging employees to give back to our local communities through volunteer and fundraising events throughout the month […] The post Mallinckrodt Employee He…

Mallinckrodt Employees Help Breathe New Life into the Scherman-Hoffman Wildlife Sanctuary in Bernardsville, NJ

October is Mallinckrodt’s Global Month of Service, a company-wide initiative encouraging employees to give back to our local communities through volunteer and fundraising events. Employees from the Global Development Operations department in Bedminster, NJ recently […] The post Mallinckrodt Employee…
Show more

Mallinckrodt Pharmaceuticals Frequently Asked Questions

  • When was Mallinckrodt Pharmaceuticals founded?

    Mallinckrodt Pharmaceuticals was founded in 1867.

  • Who are Mallinckrodt Pharmaceuticals key executives?

    Mallinckrodt Pharmaceuticals's key executives are Mark Trudeau, Spiro Gavaris and Angus Russell.

  • How many employees does Mallinckrodt Pharmaceuticals have?

    Mallinckrodt Pharmaceuticals has 3,700 employees.

  • What is Mallinckrodt Pharmaceuticals revenue?

    Latest Mallinckrodt Pharmaceuticals annual revenue is £90.4 m.

  • What is Mallinckrodt Pharmaceuticals revenue per employee?

    Latest Mallinckrodt Pharmaceuticals revenue per employee is £24.4 k.

  • Who are Mallinckrodt Pharmaceuticals competitors?

    Competitors of Mallinckrodt Pharmaceuticals include Jazz Pharmaceuticals, Hikma Pharmaceuticals and BioDelivery Sciences International.

  • Where is Mallinckrodt Pharmaceuticals headquarters?

    Mallinckrodt Pharmaceuticals headquarters is located at The Causeway, Staines-upon-Thames, Staines.

  • Where are Mallinckrodt Pharmaceuticals offices?

    Mallinckrodt Pharmaceuticals has offices in Staines, Bedminster, Hazelwood, Webster Groves and in 1 other location.

  • How many offices does Mallinckrodt Pharmaceuticals have?

    Mallinckrodt Pharmaceuticals has 5 offices.